Ratings Intuitive Surgical, Inc.

Equities

ISRG

US46120E6023

Market Closed - Nasdaq Other stock markets 04:00:00 2023-12-06 pm EST			Pre-market 09:26:20 am
310.26 ^USD	+0.24%		311.56	+0.42%

Dec. 04	Morgan Stanley Raises Intuitive Surgical Price Target to $330 From $300, Maintains Equal Weight Rating	MT
Nov. 21	It’s Nvidia Day

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 48% by 2025.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Analyst opinion has improved significantly over the past four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

With an expected P/E ratio at 68.24 and 57.18 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
INTUITIVE SURGICAL, INC.	+16.92%	109 B $	B-
THERMO FISHER SCIENTIFIC	-10.33%	191 B $	B
DANAHER CORPORATION	-16.83%	163 B $	B-
BOSTON SCIENTIFIC CORPORATION	+18.48%	80 310 M $	A-
SIEMENS HEALTHINEERS AG	+12.22%	63 346 M $	A-
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-10.80%	47 620 M $	B+
EDWARDS LIFESCIENCES CORPORATION	-6.86%	42 146 M $	B+
AGILENT TECHNOLOGIES, INC.	-13.86%	37 658 M $	A
GE HEALTHCARE TECHNOLOGIES INC.	+16.56%	30 979 M $	-
RESMED, INC.	-21.20%	24 121 M $	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes